Suppuration: Clinical Trials

13 trials for Suppuration, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 2, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Terminated 13
Phase 32Terminated 2

Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment - Chronic Urticaria, Idiopathic, Hidradenitis
Phase 2TerminatedInflaRx GmbH732025-01-022026-02-03
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
Brensocatib, Placebo - Hidradenitis Suppurativa
Phase 2TerminatedInsmed Incorporated2142024-12-162026-06-29
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
Spesolimab, Placebo - Hidradenitis Suppurativa (HS)
Phase 2 / Phase 3TerminatedBoehringer Ingelheim392024-05-082026-06-17
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
Deucravacitinib, Placebo - Hidradenitis Suppurativa
Phase 2TerminatedBeth Israel Deaconess Medical Center72023-11-302026-05-29
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
SAR444656 (KT-474), Placebo - Hidradenitis Suppurativa
Phase 2TerminatedSanofi702023-09-292025-12-11
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Ruxolitinib 1.5% Cream - Hidradenitis Suppurativa
Phase 2TerminatedMilton S. Hershey Medical Center62022-10-132026-04-28
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)
RIST4721, Placebo - Hidradenitis Suppurativa
Phase 2TerminatedAristea Therapeutics, Inc.252022-07-182023-06-13
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
Bermekimab, Adalimumab, Placebo - Hidradenitis Suppurativa
Phase 2TerminatedJanssen Research & Development, LLC1512021-10-122023-11-13
Antibiotic Irrigations for Intra-Abdominal Drains
Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo - Abdominal Abscess
Phase 2TerminatedUniversity of Iowa22019-04-012026-09-03
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
MEDI8968, Saline - Hidradenitis Suppurativa
Phase 2TerminatedAstraZeneca2242013-05-012016-09-01
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
Drug: GSK2251052, Meropenem, Placebo - Infections, Intestinal
Phase 2TerminatedGlaxoSmithKline152011-10-032017-11-29
A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS
drospirenone and ethinyl estradiol (YAZ), Placebo - Hidradenitis Suppurativa
Phase 2TerminatedMassachusetts General Hospital42008-10-012014-02-10
Safety and Effectiveness of tPA in Intra-abdominal Abscesses
Tissue Plasminogen Activator, Normal Saline - Abscess
Phase 2 / Phase 3TerminatedUniversity Health Network, Toronto352005-07-012014-01-14

Narrower conditions

Hidradenitis Suppurativa (10)  ·  Abscess (2)  ·  Abdominal Abscess (1)  ·  Chronic Urticaria (1)  ·  Hidradenitis (1)  ·  Infections (1)  ·  Intraabdominal Infections (1)  ·  Peritonitis (1)

Broader conditions

Infections (12)  ·  Bacterial Infections (10)  ·  Bacterial Infections and Mycoses (10)  ·  Skin Diseases (10)  ·  Skin Diseases, Bacterial (10)  ·  Skin Diseases, Infectious (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Sweat Gland Diseases (10)  ·  Hidradenitis (9)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Inflammation (2)  ·  Abscess (1)  ·  Chronic Disease (1)

Interventions

3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (1)  ·  Adalimumab (1)  ·  Ethinyl Estradiol (1)  ·  Injections (1)  ·  Meropenem (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  Therapeutics (1)  ·  Tissue Plasminogen Activator (1)  ·  bermekimab (1)  ·  brensocatib (1)  ·  clindamycin phosphate (1)  ·  deucravacitinib (1)  ·  drospirenone (1)  ·  drospirenone and ethinyl estradiol combination (1)

Sponsors

Aristea Therapeutics, Inc. (1)  ·  AstraZeneca (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Boehringer Ingelheim (1)  ·  GlaxoSmithKline (1)  ·  InflaRx GmbH (1)  ·  Insmed Incorporated (1)  ·  Janssen Research & Development, LLC (1)  ·  Massachusetts General Hospital (1)  ·  Milton S. Hershey Medical Center (1)  ·  Sanofi (1)  ·  University Health Network, Toronto (1)  ·  University of Iowa (1)

Countries

United States (12)  ·  Canada (7)  ·  Germany (5)  ·  Poland (5)  ·  Spain (5)  ·  Australia (3)  ·  Bulgaria (3)  ·  France (3)  ·  Greece (3)  ·  Japan (2)  ·  Netherlands (2)  ·  South Korea (2)  ·  Argentina (1)  ·  Chile (1)  ·  Czechia (1)

Top investigators

Alexandra B Kimball, MD, MPH (1)  ·  Alexandra Kimball, MD, MPH (1)  ·  Dheeraj Rajan, MD (1)  ·  Murray Asch, MD (1)  ·  Robert AK Lee, MD (1)  ·  Scott Sherman, MD (1)

NIH funding

2023 (2)